Executive Team
Richard Muruve
CEO, DIRECTOR &
CO-FOUNDER
Mr. Muruve became CEO of Arch Biopartners Inc. in 2010 after successfully co-founding and guiding the company through the transition to become publicly listed in Canadian and US markets. At the time, Arch acquired the commercial rights to several early stage therapeutic innovations discovered in academic laboratories, thereby launching the portfolio approach to drug development that Arch continues today. Since 2018, Mr Muruve has overseen the growth of the firm from being predominantly pre-clinical and research based, into a mature clinical trials company, conducting or participating in several Phase I, II and III human trials for its lead drug candidates.
Prior to his work at Arch, Mr. Muruve worked at Bank of Montreal where he spent 12 years in the Investment Banking Group as a Vice President. Mr. Muruve holds an MBA from the University of British Columbia.
Dr. Daniel Muruve MD
Chief Science Officer (CSO)
Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and holds a Canada Research Chair in Inflammation and Kidney Disease.
Andrew Bishop
Chief Financial Officer, Director
Andrew Bishop has extensive experience in financial leadership and corporate governance within the life sciences sector. He is a Partner and Co-Founder of Bingley Capital Inc., a corporate finance and advisory firm. Andrew also advises and invests in biotechnology and healthcare companies, and serves as Chief Financial Officer for both Arch Biopartners Inc and AmacaThera Inc.
Andrew has more than 20 years of experience in biotechnology and healthcare and has participated in over 100 financing, M&A and licensing transactions. He previously held senior investment banking roles, including Head of Healthcare Investment Banking at HSBC, advising biotechnology and pharmaceutical companies. He has also held board and leadership positions with organizations including Liminal BioSciences and Willow Breast & Hereditary Cancer Support.
Aaron Benson
Director of Communications & CliNICAL DATA MANAGEMENT
As the Director of Communications, Aaron merges traditional communications and design techniques with contemporary technology, creative and digital practices to deliver a concise and clear voice for the company. As the leader of the Clinical Data Management team, Aaron combines his deep experience bridging enterprise data systems with day-to-day applications to support the company and its clinical trials. Aaron’s career in communications and design has included the delivery of design systems, interface design, user experience, and front-end development for a diverse range of corporate and business clients in sectors such as finance, insurance, technology, biotech, engineering, and real estate. His leadership roles in multiple studios and communications teams has involved managing substantial brand systems and marketing campaigns for prominent financial institutions, along with national clients in arts, dance, theatre, and philanthropy.
Dr. Arthur Lau Ph. D
Director of Clinical Trials and Research Scientist
Arthur Lau is the Director of Clinical Trials at Arch Biopartners and a Research Scientist in Dr. Daniel Muruve’s research program at the University of Calgary. He completed a B.Sc. with Honours at the University of Toronto and a Ph.D. at the University of Western Ontario with a focus on kidney transplantation and immunology. As a postdoctoral fellow at the University of Calgary under the mentorship of Dr. Muruve, he continued his research on acute kidney injury and immunology including publications describing the use of LSALT peptide in renal disease. His current research focus is on elucidating mechanisms of immune surveillance in the kidney and developing therapeutics against acute kidney injury. Arthur joined the Arch Biopartners’ team as a Project Manager primarily managing the development of the LSALT peptide/Metablok portfolio and its related technologies.
